In L-TTF2 patients, circulating CXCR3+CD8+-T-cells were still elevated after failure of first-line CTX, mirroring the immune-enriched nature of the treatment-naïve tumor tissues with e.g., cytotoxic CXCR3+CD8+-T-cell infiltration. The gene discussed is CD8A; the disease is neoplasm.